[The impact of controlling bone remodeling in rheumatoid arthritis.].

Rheumatoid arthritis(RA)is associated with increased bone turnover and early bone loss, which lead to increased fracture risk and progressive joint destruction. Pro-inflammatory cytokines, such as IL(interleukin)-17, TNF-α(tumor necrosis factor alpha), IL-1, and IL-6 induce the expression of RANKL(receptor activation of nuclear factor κB ligand)from synovial fibroblasts. RANKL promotes osteoclasts differentiation and activation, and Denosumab, an anti-RANKL monoclonal antibody, inhibits both systemic bone loss and focal bone erosion of RA.